secwatch.observer — SEC 8-K summary
======================================

Issuer:     CV Sciences, Inc. (CVSI)
CIK:        0001510964
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001193125-26-126211
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CV Sciences FY2025 revenue down 12% to $13.8M; adjusted EBITDA loss narrows to $0.3M
--------------------------------------------------------------------------------

- Revenue $13.8M for FY2025 vs $15.7M in 2024, a 12.2% decline on lower volume and regulatory headwinds.
- Gross margin improved to 49.0% from 45.6%; operating loss reduced to $0.5M from $2.2M.
- Adjusted EBITDA loss was $0.3M, improved from $0.8M in 2024; Q4 2025 delivered positive adjusted EBITDA of $0.1M.
- Cash balance $0.3M at year-end; completed debt restructuring in Q1 2026 to strengthen financial position.
- Launched 39 new products since Jan 2023; new products contributed 39% of FY2025 net revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1510964/000119312526126211/0001193125-26-126211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1510964/000119312526126211/cvsi-20260326.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-126211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer